Symbollon Pharmaceuticals Establishes Commercialization Advisory Board

MEDFIELD, MA--(Marketwire - March 01, 2010) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) (www.symbollon.com) has announced today the formation of its first Commercialization Advisory Board to spearhead the launch and ongoing sales and distribution of its proprietary and patented molecular iodine product, Iogen™ specifically formulated as a dietary supplement for improved women's breast health. The Board members have played an integral role in the development of the newly designed retail website, www.buyiogen.com, and in the commercial launch of Iogen™ to the public which is anticipated to begin March 4, 2010.

The board is made up of a team of commercialization experts who, when combined, have many decades of experience in the retail sales, distribution, marketing and advertising industries. Roger Wist and Mike Griak, of Wist-Griak & Associates located in Carlsbad, CA, have over 60 years of combined sales, marketing and advertising experience. Roger has been integral to several start-ups and has a vertical understanding of all marketing components and package design and how to balance them to be both impactful and cost effective. Mike has an extensive background in the advertising world having launched and managed multiple brands for companies such as Schwan's, Pillsbury and Hormel Foods. After graduating with a MBA from Boston College, he gained experience working with some of the largest advertising agencies in the midwest. Symbollon believes that Mike's and Roger's experience and philosophies creating a relevant and compelling brand identity and then delivering that brand through cost effective packaging, advertising, promotions and partnerships will push Symbollon and its products to the forefront of women's minds.

David Ghiz led the retail growth and expansion of Paddock Pool Construction Company from 1985 until the family sold the business in 2005. Under David's and his brother Lewis' direction, Paddock grew from 4 retail locations in the Phoenix, AZ market to 16 locations throughout Arizona and southern Nevada and grew sales from $18 million in 1985 to nearly $150 million in 2004. Paddock grew to be the second largest specialty retailer of backyard living products and pool supplies in the United States and the largest in the two markets the company served. Symbollon believes that David's experience and philosophies with customer service, vendor negotiations, logistics and his expertise in developing distribution channels and inventory control systems will bring added value to Symbollon as product and category expansions are developed. David clearly understands that controlling costs and driving inventory turns are key components to maximizing ROI.

This newly formed Commercialization Advisory Board will assist Symbollon with all aspects of positioning the company as the premier women's health and wellness biotechnical company in the world. It will include the marketing and selling of Iogen™ and other brands and products under development by the company, including the personal lubricant product Sylk™, which the company announced it is in the process of acquiring.

Symbollon Pharmaceuticals, Inc. Resources:

--  Corporate Profile: http://symbollon.com/corporate_profile.htm 
--  FAQ: http://symbollon.com/faq.htm 
--  Technology Overview: http://symbollon.com/technology_overview.htm 

About Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA)
Symbollon is a specialty biotechnology company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobials uses. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.

Forward-Looking Statement: This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to successfully commercialize IoGen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) the Company will be able to enter into new arrangements with corporate partners, (iv) we will be able to complete the acquisition of New Zealand Pure under the terms of the letter of intent, (v) Symbollon will be able to commercialize other products and (vi) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.